Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
Items 601–700 of 1,000
cDNA cloning of Runx family genes from the pufferfish (Fugu rubripes)
Ng, C. E. L., Osato, M., Tay, B. H., Venkatesh, B., & Ito, Y. (2007) · Gene · doi:10.1016/j.gene.2007.05.014 · Cited by 23
RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity
Chin, D. W. L., Sakurai, M., Nah, G. S. S., Du, L. Z., Jacob, B., Yokomizo, T., Matsumura, T., Suda, T., Huang, G., Fu, X.-Y., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.105 · Cited by 22
Smith, M. L., & McKerrell, T. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch3 · Cited by 22
Neuroblastoma cell proliferation is sensitive to changes in levels of RUNX1 and RUNX3 protein
Inoue, K., & Ito, Y. (2011) · Gene · doi:10.1016/j.gene.2011.05.016 · Cited by 22
Megakaryoblastic Disorders in Children
Lorsbach, R. B. (2004) · Pathology Patterns Reviews · doi:10.1309/y57ugte36pgq2nv6 · Cited by 25
Genomic Assessment of Pediatric Acute Leukemia
Mullighan, C. G., Flotho, C., & Downing, J. R. (2005) · The Cancer Journal · doi:10.1097/00130404-200507000-00003 · Cited by 23
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML
Cammenga, J. (2005) · Leukemia · doi:10.1038/sj.leu.2403894 · Cited by 27
A leukemogenic twist for GATA1
Look, A. T. (2002) · Nature Genetics · doi:10.1038/ng960 · Cited by 22
Loss of heterozygosity in childhood de novo acute myelogenous leukemia
Sweetser, D. A., Chen, C.-S., Blomberg, A. A., Flowers, D. A., Galipeau, P. C., Barrett, M. T., Heerema, N. A., Buckley, J. D., Woods, W. G., Bernstein, I. D., et al. (2001) · Blood · doi:10.1182/blood.v98.4.1188 · Cited by 22
Manikandan, M., Raksha, G., & Munirajan, A. K. (2012) · Cancer Informatics · doi:10.4137/cin.s10176 · Cited by 22
Cobaleda, C., Godley, L. A., Nichols, K. E., Włodarski, M. W., & Sánchez-García, I. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1091 · Cited by 23
“8) as the cause of a familial platelet disorder with predisposition to myeloid malignancy.”
BackgroundGSTT1andGSTM1polymorphisms and myelodysplastic syndrome risk: a systematic review and meta‐analysis
Dahabreh, I. J., Giannouli, S., Gota, V., & Voulgarelis, M. (2009) · International Journal of Cancer · doi:10.1002/ijc.24940 · Cited by 21
Gene of the issue: RUNX1 mutations and inherited bleeding
Morgan, N. V., & Daly, M. E. (2017) · Platelets · doi:10.1080/09537104.2017.1280151 · Cited by 21
“The molecular genetic cause of FPD/AML was first elucidated by linkage studies which mapped the underlying genetic defect to a region on human chromosome 21q [3].”
Akpan, I. J., Osman, A. E. G., Drazer, M. W., & Godley, L. A. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0473-7 · Cited by 21
A new angle on a pervasive oncogene
Cleary, M. L. (1999) · Nature Genetics · doi:10.1038/13761 · Cited by 22
ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1
Krapf, G., Kaindl, U., Kilbey, A., Fuka, G., Inthal, A., Joas, R., Mann, G., Neil, J. C., Haas, O. A., & Panzer‐Grümayer, E. R. (2010) · Oncogene · doi:10.1038/onc.2010.53 · Cited by 21
“In contrast, transfection of NIH3T3 cells with an expression vector with a point mutation in the runt domain (E/RR201Q) that had been earlier shown to diminish DNA binding, but not heterodimerization with CBFb (Song et al., 1999; Li et al., 2003), resulted in only partial reduction of RUNX1-induced activation (Figure…”
BackgroundInfluentialCytogenetics of Acute Leukemia
Heerema, N. A., & Raimondi, S. C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_18 · Cited by 21
Duployez, N., Lejeune, S., Renneville, A., & Preudhomme, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1257936 · Cited by 21
“finally identified germline RUNX1 mutations (more rarely deletions) as causative of the FPD/AML phenotype in 6 unrelated pedigrees [3].”
BackgroundThe inv(16) Cooperates with ARF Haploinsufficiency to Induce Acute Myeloid Leukemia
Moreno–Miralles, I., Pan, L., Keates‐Baleeiro, J., Goodwin, K. D., Yang, C., Kim, H., Thompson, M. A., Klug, C. A., Cleveland, J. L., & Hiebert, S. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506855200 · Cited by 23
Turkalj, S., Jakobsen, N. A., Groom, A., Metzner, M., Riva, S. G., Gür, E. R., Usukhbayar, B., Salazar, M. A., Hentges, L. D., Mickute, G., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.012 · Cited by 20
Hematopoietic transcription factor mutations and inherited platelet dysfunction
Songdej, N., & Rao, A. K. (2015) · F1000Prime Reports · doi:10.12703/p7-66 · Cited by 24
“Some of the TF mutations have prognostic and treatment implications beyond the platelet defect, such as the association of myeloid malignancies with mutations inRUNX1 and donor selection for hematopoietic stem cell transplant [6,7,21].”
BackgroundLee, K., Ahn, H.-S., Estevez, B., & Poncz, M. (2022) · Blood · doi:10.1182/blood.2022017561 · Cited by 21
Self-citationPan, L., Huang, Y., Wang, M., Zhuang, X.-E., Luo, D.-F., Guo, S., Zhang, Z.-S., Huang, Q., Lin, S., & Wang, S. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.67 · Cited by 20
Mao, G., Songdej, N., Voora, D., Goldfinger, L. E., Carpio‐Cano, F. E. D., Myers, R. A., & Rao, A. K. (2017) · Circulation · doi:10.1161/circulationaha.116.023711 · Cited by 21
Nakano, T. A., Lau, B. W., Dickerson, K. E., Włodarski, M. W., Pollard, J. A., Shimamura, A., Hofmann, I., Sasa, G., Elghetany, T. M., Cada, M., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28652 · Cited by 20
Decker, M., Lammens, T., Ferster, A., Erlacher, M., Yoshimi, A., Niemeyer, C. M., Ernst, M. P. T., Raaijmakers, M. H. G. P., Duployez, N., Flaum, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01200-w · Cited by 20
Thornton, M. A., Zhang, C., Kowalska, M. A., & Poncz, M. (2002) · Blood · doi:10.1182/blood-2002-05-1307 · Cited by 20
Self-citationOdenike, O. M., Anastasi, J., & Beau, M. M. L. (2011) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2011.08.005 · Cited by 21
Gao, Q. C., Horwitz, M. S., Roulston, D., Hagos, F., Zhao, N., Freireich, E. J., Golomb, H. M., & Olopade, O. I. (2000) · Genes Chromosomes and Cancer · Cited by 20
AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia
Barton, K., & Nucifora, G. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200003)22:3<214::aid-bies2>3.0.co;2-i · Cited by 20
Pharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia
Knoche, E., McLeod, H. L., & Graubert, T. A. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.5.719 · Cited by 19
Inherited platelet dysfunction and hematopoietic transcription factor mutations
Songdej, N., & Rao, A. K. (2016) · Platelets · doi:10.1080/09537104.2016.1203400 · Cited by 19
Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications
Liu, Y.-C., Eldomery, M. K., Maciaszek, J. L., & Klco, J. M. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023420 · Cited by 16
Nagamachi, A., Htun, P. W., Ma, F., Miyazaki, K., Yamasaki, N., Kanno, M., Inaba, T., Honda, Z., Okuda, T., Oda, H., et al. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2010.07.015 · Cited by 19
“5 dpc were blotted with an anti-Runx1 (upper panel) or an anti-β-actin antibody (lowe more, a haploinsufficiency of Runx1 was detected in a hereditary familiar platelet disorder in which patients are predisposed to leukemic development (Song et al., 1999).”
MethodInfluentialFörster, A., Decker, M., Schlegelberger, B., & Ripperger, T. (2022) · Cancers · doi:10.3390/cancers14143431 · Cited by 19
“Regarding germline mutations, RUNX1 was first associated with leukemia predisposition in 1999 [25].”
BackgroundRoumier, C., Lejeune‐Dumoulin, S., Renneville, A., Goethgeluck, A. S., Philippe, N., Fenaux, P., & Preudhomme, C. (2006) · Leukemia · doi:10.1038/sj.leu.2404097 · Cited by 19
Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Nardi, V., & Hasserjian, R. P. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.10.004 · Cited by 20
Badin, M., Iyer, J. K., Chong, M., Graf, L., Rivard, G., Waye, J. S., Paterson, A. D., Paré, G., & Hayward, C. P. M. (2017) · Haemophilia · doi:10.1111/hae.13169 · Cited by 22
Acute myeloid leukaemia in children
Langmuir, P. B., Aplenc, R., & Lange, B. J. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2000.0117 · Cited by 21
Matsuura, S., Komeno, Y., Stevenson, K. E., Biggs, J. R., Lam, K., Tang, T., Lo, M., Cong, X., Yan, M., Neuberg, D. S., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404533 · Cited by 20
Click, E. S., Cox, B., Olson, S. B., Grompe, M., Akkari, Y. M. N., Moreau, L. A., Shimamura, A., Sternen, D. L., Liu, Y. J., Leppig, K. A., et al. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34024 · Cited by 18
Hereditary Leukemia Due to Rare RUNX1c Splice Variant (L472X) Presents with Eczematous Phenotype
Sorrell, A., Espenschied, C. R., Wang, W. J., Weitzel, J. N., Chu, S., Parker, P. A., Saldivar, J., & Bhatia, R. (2012) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2012.37110 · Cited by 18
“Most of these reports, summarized in Figure 1(a), describe heterozygous germline mutations that cluster in the amino-terminal (N-terminal) region of the gene within the DNA-binding runt homology domain [3-31].”
BackgroundRoles of the RUNX1 Enhancer in Normal Hematopoiesis and Leukemogenesis
Liau, W., Ngoc, P. C. T., & Sanda, T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_10 · Cited by 18
Therapeutic Vulnerabilities of Transcription Factors in AML
Khan, I., Eklund, E. A., & Gartel, A. L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0115 · Cited by 19
“RUNX1 is indispensable for the establishment of definitive hematopoiesis, and heterozygous germline mutations result in a highly penetrant familial platelet disorder with a predisposition to AML (24).”
BackgroundAccurate germline RUNX1 variant interpretation and its clinical significance
Feurstein, S. K., Zhang, L., & Dinardo, C. D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003304 · Cited by 18
RUNX1-RUNX1 Homodimerization Modulates RUNX1 Activity and Function
Li, D., Sinha, K. K., Abdul‐Hay, M., Rinaldi, C. R., Saunthararajah, Y., & Nucifora, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700074200 · Cited by 20
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia
Micci, F., Panagopoulos, I., Haugom, L., Andersen, H. K., Tjønnfjord, G. E., Beiske, K., & Heim, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.016 · Cited by 18
“1, and RUNX1 [23–27].”
BackgroundPais, A. P., Kadam, P. S. A., Raje, G. C., Banavali, S. D., Parikh, P. M., Kurkure, P. A., Arora, B., Gujral, S., Kumar, S. A., & Badrinath, Y. (2008) · Pediatric Hematology and Oncology · doi:10.1080/08880010802237450 · Cited by 18
Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML
Duployez, N., Martin, J., Khalife‐Hachem, S., Benkhelil, R., Saada, V., Marzac, C., Auger, N., Marceau‐Renaut, A., Favier, R., Ballerini, P. F., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000203 · Cited by 18
“The R139Q mutation has been already described in FPD/AML patients.(1,5) It affects the Runt homology domain (RHD) of RUNX1, which binds to DNA and to the other member of the CBF complex,”
BackgroundRUNX1 suppression induces megakaryocytic differentiation of UT-7/GM cells
Nagai, R., Matsuura, E., Hoshika, Y., Nakata, E., Nagura, H., Watanabe, A., Komatsu, N., Okada, Y., & Doi, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.057 · Cited by 18
Belloni, E., Trubia, M., Mancini, M., Derme, V., Nanni, M., Lahortiga, I., Riccioni, R., Confalonieri, S., Lo‐Coco, F., Fiore, P. P. D., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20081 · Cited by 20
“Our data further strengthen the hypothesis that haploinsufficiency might be an important mechanism in the molecular pathogenesis of leukemia, as described for the AML1 (RUNX1) gene in cases of familial platelet disorders with predisposition to acute myelogenous leukemia (Song et al., 1999).”
BackgroundThrombocytopenia in the Newborn
Roberts, I. A. G., & Chakravorty, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00044-8 · Cited by 18
FLT3 mutations are associated with other molecular lesions in AML
Carnicer, M. J., Nomdedeu, J. F., Lasa, A., Estivill, C., Brunet, S., n, A. A. X., & Sierra, J. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00125-5 · Cited by 18
Familial myelodysplastic syndromes, monosomy 7/trisomy 8, and mutator effects
Maserati, E., Minelli, A., Menna, G., Cecchini, M. P., Bernardo, M. E., Rossi, G., Filippi, P. D., Curto, F. L., Danesino, C., Locatelli, F., et al. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00271-1 · Cited by 18
Pediatric leukemia susceptibility disorders: manifestations and management
McReynolds, L. J., & Savage, S. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.242 · Cited by 20
“Heterozygous pathogenic germline variants in RUNX1 were identified as the cause of FPD in 1999.(25) Patients with FPD have thrombocytopenia and bleeding tendency as a result of platelet dysfunction and dense granule storage pool deficiency.”
BackgroundIntroduction to Acquired and Inherited Bone Marrow Failure
Sieff, C. A. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.04.008 · Cited by 17
Molecular Genetics of Cleidocranial Dysplasia
Motaei, J., Salmaninejad, A., Jamali, E., Khorsand, I., Ahmadvand, M., Shabani, S., Karimi, F., Nazari, M. S., Ketabchi, G., & Naqipour, F. (2020) · Fetal and Pediatric Pathology · doi:10.1080/15513815.2019.1710792 · Cited by 22
B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations
Six, K. A., Gerdemann, U., Brown, A. L., Place, A. E., Cantor, A. B., Kutny, M. A., & Avagyan, S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004653 · Cited by 17
“Patients withRUNX1-FPDmay have qualitative and/or quantitative defects in platelets manifesting as bleeding symptoms.(1) With a median onset at 29 years of age,(2) the most common types of hematologic malignancies are myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with rare diagnoses of T-cell acute…”
BackgroundJalagadugula, G. S., Goldfinger, L. E., Mao, G., Lambert, M. P., & Rao, A. K. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014274 · Cited by 18
Ng, I. K., Lee, J., Ng, C., Kosmo, B., Chiu, L., Seah, E., Mok, M. M. H., Tan, K. M. L., Osato, M., Chng, W. J., et al. (2018) · Biomarker Research · doi:10.1186/s40364-018-0130-2 · Cited by 18
“[6] Detection of heterozygous RUNX1 mutations in six FPD/AML pedigrees, mostly found within the Runt domain.”
Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories
Kellaway, S. G., Keane, P., Edginton‐White, B., Regha, K., Kennett, E., & Bonifer, C. (2021) · Life Science Alliance · doi:10.26508/lsa.202000864 · Cited by 17
“However, RUNX1 point mutations can run in families (Song et al, 1999) and permit haematopoiesis which is in line with the results shown here.”
BackgroundResultInfluentialRestoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation
Krutein, M. C., Hart, M. R., Anderson, D. J., Jeffery, J., Kotini, A. G., Dai, J., Chien, S. S., DelPriore, M. R., Borst, S., Maguire, J. A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002709 · Cited by 19
“T), which enforces the use of a cryptic splice acceptor in exon 4 with a resultant frameshift that causes premature termination.(8) We prepared an isogenic control using CRISPR-Cas9–based, homology-directed repair to correct the germline mutation.”
MethodDeluche, L., Joha, S., Corm, S., Daudignon, A., Geffroy, S., Quief, S., Villenet, C., Kerckaert, J., Laï, J., Preudhomme, C., et al. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20611 · Cited by 17
“Song et al. (1999) suggested that inactivation of one RUNX1 allele was sufficient to induce predisposition to develop acute leukemia in familial platelet thrombocytopenia.”
BackgroundInherited Bone Marrow Failure Syndromes
Dror, Y. (2006) · Wiley eBooks · doi:10.1002/9780470987001.ch3 · Cited by 17
Clark, J., Smith, F. O., & Arceci, R. J. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200301000-00006 · Cited by 20
Linden, T., Schnittger, S., Groll, A. H., Juergens, H., & Rössig, C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08370.x · Cited by 16
“Of note, direct sequencing of RUNX1 alone may fail to detect germline copy number variations and intragenic RUNX1 deletions (Song et al, 1999; Jongmans et al, 2010), emphasizing the need for complementary methods, such as single nucleotide polymorphism analysis.”
BackgroundMethodFranchini, M., Lippi, G., Veneri, D., Targher, G., Zaffanello, M., & Guidi, G. C. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.08.010 · Cited by 16
Okada, Y., Watanabe, M., Nakai, T., Kamikawa, Y., Shimizu, M., Fukuhara, Y., Yonekura, M., Matsuura, E., Hoshika, Y., Nagai, R., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12355 · Cited by 19
Mutations of RUNX1 in families with inherited thrombocytopenia
Rocco, D. D., Melazzini, F., Marconi, C., Pecci, A., Bottega, R., Gnan, C., Palombo, F., Giordano, P., Coccioli, M. S., Glembotsky, A. C., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24703 · Cited by 16
“FPD/AML is caused by different, usually private, mutations of RUNX1, a gene encoding the DNA binding subunit (also known as CBF-alpha) of the core binding factor (CBF) transcription complex.(2) The N-terminal domain of RUNX1 (runt-homologous domain) mediates DNA binding and heterodimerization to CBF-beta, the other su…”
BackgroundMyeloid Neoplasms with Germline Predisposition
Geyer, J. T. (2018) · Pathobiology · doi:10.1159/000490311 · Cited by 16
Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia
Ochi, Y., & Ogawa, S. (2021) · Cancers · doi:10.3390/cancers13061232 · Cited by 19
“RUNX1 mutations are also found in the germline and cause familial platelet disorder with a predisposition to AML [64,65].”
BackgroundMolecular genetics of acute lymphoblastic leukemia
Ferrando, A. A., Rubnitz, J. E., & Look, A. T. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.011 · Cited by 16
Qiao, Y., Ogawa, S., Hangaishi, A., Yuji, K., Izutsu, K., Kunisato, A., Imai, Y., Wang, L., Hosoya, N., Nannya, Y., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402919 · Cited by 17
Role of Nuclear Receptor Corepressors in Leukemogenesis
Guidez, F., & Zelent, A. (2001) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-10595-5_9 · Cited by 19
Myelodysplastic Syndromes: Contemporary Biologic Concepts and Emerging Diagnostic Approaches
Vergilio, J., & Bagg, A. (2003) · Pathology Patterns Reviews · doi:10.1309/t8df-xexm-ylhw-51dg · Cited by 16
Ernst, M. P. T., Versluis, J., Valk, P. J. M., Bierings, M., Tamminga, R. Y. J., Hooimeijer, H. L., Döhner, K., Gresele, P., Tawana, K., Langemeijer, S. M. C., et al. (2025) · HemaSphere · doi:10.1002/hem3.70057 · Cited by 15
Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering
Jung, M., Dunbar, C. E., & Winkler, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.180 · Cited by 16
Molecular Basis of Hematological Disease Caused by Inherited or Acquired RUNX1 Mutations
Kellaway, S. G., Coleman, D. J. L., Cockerill, P. N., Raghavan, M., & Bonifer, C. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.009 · Cited by 15
Chloride binding by the AML1/Runx1 transcription factor studied by NMR
Wolf‐Watz, M., Bäckström, S., Grundström, T., Sauer, U. H., & Härd, T. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02390-5 · Cited by 15
Fey, M. F., & Surbek, D. (2007) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-71274-9_10 · Cited by 15
Hirai, H. (2002) · International Journal of Hematology · doi:10.1007/bf03165120 · Cited by 21
Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse
Shannon, K., Beau, M. M. L., Largaespada, D. A., & Killeen, N. P. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0372 · Cited by 15
Egeler, R. M., & Willman, C. L. (2000) · Medical and Pediatric Oncology · Cited by 15
Self-citationSendker, S., Awada, A., Domagalla, S., Sendker, M., Orhan, E., Hoffmeister, L. M., Antoniou, E., Niktoreh, N., Reinhardt, D., Neuhoff, N. V., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01919-8 · Cited by 14
Modeling of hematologic malignancies by iPS technology
Arai, S., Miyauchi, M., & Kurokawa, M. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.006 · Cited by 14
“The disease is associated with inherited mutation in the RUNX1 gene [13].”
BackgroundTranscription factors in megakaryocytes and platelets
Yuan, H., Liu, Y., Zhang, J., Dong, J., & Zhao, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140501 · Cited by 15
“One report found that 22 patients in a family with autosomal dominant thrombocytopenia had mutations in the RUNX1 gene (19) and 6 of them developed hematologic malignancies (20).”
BackgroundLangabeer, S. E., Owen, C., McCarron, S. L., Fitzgibbon, J., Smith, O. P., O'Marcaigh, A. S., & Browne, P. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01513.x · Cited by 14
“FPD ⁄AML kindreds possess germ-line mutations of RUNX1 (previously AML1) (1) that encodes a transcription factor essential for definitive haematopoiesis and myeloid differentiation, commonly dysregulated by translocations, mutations or amplification in de novo and secondary acute leukaemias and MDS (2).”
BackgroundFunk, R. K., Maxwell, T. J., Izumi, M., Edwin, D., Kreisel, F. H. C., Ley, T. J., Cheverud, J. M., & Graubert, T. A. (2008) · Blood · doi:10.1182/blood-2008-01-132084 · Cited by 14
AML1/RUNX1 gene point mutations in childhood myeloid malignancies
Migas, A. A., Savva, N. N., Mishkova, V., & Aleinikova, O. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22980 · Cited by 17
“174Arg>Gln[32,33,34] # RUNT 46, XX [20] Death in relapse 4 AML M4 16/F g.”
BackgroundI Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions
Gondek, L. P., & Dezern, A. E. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0224-3 · Cited by 15
Christensen, R. D., Wiedmeier, S. E., & Yaish, H. M. (2013) · Journal of Perinatology · doi:10.1038/jp.2012.53 · Cited by 14
Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction
Wang, Y., Meng, R., Hayes, V., Fuentes, R., Yu, X., Abrams, C. S., Heijnen, H. F. G., Blobel, G. A., Marks, M. S., & Poncz, M. (2011) · Blood · doi:10.1182/blood-2011-06-363580 · Cited by 15
Self-citationOncogènes et leucémies : historique et perspectives
Gisselbrecht, S. (2003) · médecine/sciences · doi:10.1051/medsci/2003192201 · Cited by 17
Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary
Király, A. P., Kállay, K. M., Gángó, A., Kellner, Á., Egyed, M., Szőke, A., Kiss, R., Valyi-Nagy, I. T., Csomor, J., Matolcsy, A., et al. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0216-4 · Cited by 15
Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree
Tawana, K., Wang, J., Király, P. A., Kállay, K. M., Benyó, G., Zombori, M., Csomor, J., Seraihi, A. A., Rio‐Machín, A., Matolcsy, A., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2017.80 · Cited by 14
Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells
Kim, H., & Schaniel, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02243 · Cited by 15
“An example is familial platelet disorder with a tendency to develop acute myeloid leukemia (FPD/AML) that is caused by inherited monoallelic mutations in RUNX1 (80).”
BackgroundKoschade, S. E., Stratmann, J., Miesbach, W., Steffen, B., Serve, H. L., Finkelmeier, F., Brandts, C., & Balló, O. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13718 · Cited by 16
Reducing the Genotoxic Potential of Retroviral Vectors
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-248-3_12 · Cited by 15
“Though most safety concerns associated with insertional mutagenesis have to do with gammaretroviral vectorinduced transcriptional activation of genes, it is not unreasonable to assume that haploinsufficiency of tumor suppressor genes due to lentiviral vector-mediated gene disruption could predispose toward malignancy…”
BackgroundDowdy, C. R., Frederick, D., Zaidi, S. K., Colby, J. L., Lian, J. B., van Wijnen, A. J., Gerstein, R. M., Stein, J. L., & Stein, G. S. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.06.006 · Cited by 15
“This finding was unexpected because conditional Runx1 ablation is known to cause thrombocytopenia [34,36].”
BackgroundChromosomal deletions and tumor suppressor genes in prostate cancer
Dong, J. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-48143-x_4 · Cited by 14
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.